Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET
Company Participants
Rick Barry - President & Chief Executive Officer
Eric Schoen - Chief Financial Officer
Conference Call Participants
Vernon Bernardino - H.C. Wainwright
Elemer Piros - Rodman
Operator
Ladies and gentlemen, welcome to Cassava Sciences Report for the Third Quarter 2024. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this audio webcast is being recorded.
During this call and the question-and-answer session afterwards, representatives of Cassava Sciences may make what are known as forward-looking statements. A forward-looking statement is one that is not historical fact. Forward-looking statements are not guarantees, and they involve risks, uncertainties and assumptions. Such statements represent current expectations or beliefs concerning future events or future performance.
Forward-looking statements are predictions only based upon information currently available to the company. Actual events or results could differ materially from those made in any forward-looking statement due to a number of factors, risks and uncertainties. Please refer to Cassava Sciences' recent filings with the SEC, including Forms 10-K and 10-Q for a description of the factors that could cause the events or results to differ materially from those made in forward-looking statements.
Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live webcast, November 7, 2024. Except as required by law, the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast.
It's now my pleasure to turn today's meeting over to Rick Barry, President and Chief Executive Officer. The floor is yours.
Rick Barry
Well, thank you, Noel, for the introduction. Good morning, everyone, and thank you for joining us.
With me today is Chris Cook, our Swiss Army Knife and also our General Counsel, as well as Eric Schoen, who I think of as the Chancellor of the Exchequer, also known as our Chief Financial Officer. Dr. Jim Kupiec, our Chief Medical Officer and the star of the August investor call, will not be able to join us today.
As you know, we announced the last patient/last visit of our first Phase 3 trial, RETHINK-ALZ, several weeks ago. Database cleanup is ongoing. This is a routine process that takes place at the end of every clinical trial. The purpose is to ensure the accuracy of all information in the database before it is locked and the statistical analysis begins. We expect to announce the top-line results of the trial before the end of this year.